IL6 and congenital rubella syndrome: Furthermore, preclinical studies have shown that IL-6 deficient mice still develop CRS symptoms when treated with CAR-T cells (65) suggesting targeting IL-6 alone may not be sufficient in all patients and additional therapeutic strategies are needed to treat both CRS and neurotoxicity.